Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals (NASDAQ: ARWR) launched 'We'll Get There Soon,' a disease awareness campaign for Familial Chylomicronemia Syndrome (FCS) on FCS Awareness Day. The initiative includes a website, www.LowerTriglycerides.com, and social media presence to support the FCS community. The campaign features Julie Klueckman's story, highlighting the challenges of living with FCS, including a decade-long diagnosis journey, multiple hospitalizations, and the need to maintain an extremely low-fat diet of up to 20 grams daily. The campaign aims to educate about maintaining triglyceride levels below 500 mg/dL to reduce acute pancreatitis risk and bring hope to those affected by this rare condition.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) ha lanciato 'Arriveremo Presto', una campagna di sensibilizzazione sulla malattia per la Sindrome da Chilomicronemia Familiare (FCS) in occasione della Giornata di Sensibilizzazione sulla FCS. L'iniziativa include un sito web, www.LowerTriglycerides.com, e una presenza sui social media per supportare la comunità FCS. La campagna presenta la storia di Julie Klueckman, evidenziando le sfide di vivere con la FCS, tra cui un percorso diagnostico lungo un decennio, numerose ospedalizzazioni e la necessità di mantenere una dieta estremamente povera di grassi, fino a 20 grammi al giorno. L'obiettivo della campagna è educare riguardo al mantenimento dei livelli di trigliceridi al di sotto di 500 mg/dL per ridurre il rischio di pancreatite acuta e portare speranza a coloro che sono colpiti da questa rara condizione.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) lanzó 'Llegaremos Pronto', una campaña de concienciación sobre la enfermedad para el Síndrome de Quiomicronemia Familiar (FCS) en el Día de Concienciación sobre la FCS. La iniciativa incluye un sitio web, www.LowerTriglycerides.com, y una presencia en redes sociales para apoyar a la comunidad FCS. La campaña presenta la historia de Julie Klueckman, destacando los desafíos de vivir con la FCS, incluyendo una década de búsqueda diagnóstica, múltiples hospitalizaciones y la necesidad de mantener una dieta extremadamente baja en grasas, de hasta 20 gramos diarios. La campaña tiene como objetivo educar sobre el mantenimiento de los niveles de triglicéridos por debajo de 500 mg/dL para reducir el riesgo de pancreatitis aguda y brindar esperanza a quienes están afectados por esta rara condición.
애로우헤드 제약(표준: ARWR)는 FCS 인식의 날에 가족성 키로미크론 혈증 증후군 (FCS)을 위한 질병 인식 캠페인인 '곧 도착할 것입니다'를 시작했습니다. 이 캠페인은 FCS 커뮤니티를 지원하기 위한 웹사이트(www.LowerTriglycerides.com)와 소셜 미디어 존재를 포함합니다. 캠페인은 여러 병원에 입원하고, 진단 과정을 10년 동안 겪어야 했던 Julie Klueckman의 이야기를 특징으로 하여 FCS와 함께 살아가는 도전 과제를 강조합니다. 또한 매일 20그램 이하의 극도로 저지방 식단을 유지해야 하는 필요성도 말합니다. 이 캠페인은 급성 췌장염의 위험을 줄이기 위해 트리글리세리드 수치를 500 mg/dL 이하로 유지하는 방법에 대해 교육하고, 이 희귀 질환으로 영향을 받고 있는 사람들에게 희망을 전하는 것을 목표로 하고 있습니다.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) a lancé 'Nous y arriverons bientôt', une campagne de sensibilisation à la maladie pour le Syndrome de Chylomicronémie Familiale (FCS) à l'occasion de la Journée de Sensibilisation à la FCS. L'initiative comprend un site web, www.LowerTriglycerides.com, et une présence sur les réseaux sociaux pour soutenir la communauté FCS. La campagne met en avant l'histoire de Julie Klueckman, soulignant les défis de vivre avec la FCS, y compris un parcours de diagnostic de dix ans, de multiples hospitalisations et le besoin de maintenir un régime alimentaire extrêmement pauvre en graisses, limité à 20 grammes par jour. L'objectif de la campagne est d'éduquer sur le maintien des niveaux de triglycérides en dessous de 500 mg/dL pour réduire le risque de pancréatite aiguë et apporter de l'espoir aux personnes touchées par cette maladie rare.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) hat 'Bald sind wir da' gestartet, eine Kampagne zur Sensibilisierung für Familiale Chylomikronämie-Syndrom (FCS) am Tag der FCS-Sensibilisierung. Die Initiative umfasst eine Webseite, www.LowerTriglycerides.com, und eine Präsenz in sozialen Medien zur Unterstützung der FCS-Gemeinschaft. Die Kampagne stellt die Geschichte von Julie Klueckman vor und hebt die Herausforderungen hervor, mit FCS zu leben, einschließlich einer zehnjährigen diagnostischen Reise, mehrfacher Krankenhausaufenthalte und der Notwendigkeit, eine extrem fettreduzierte Diät mit bis zu 20 Gramm täglich aufrechtzuerhalten. Ziel der Kampagne ist es, Aufklärung über die Aufrechterhaltung der Triglyceridwerte unter 500 mg/dL zu bieten, um das Risiko einer akuten Pankreatitis zu verringern und den Betroffenen dieser seltenen Erkrankung Hoffnung zu geben.
- None.
- None.
- The launch of this campaign is about imagining a future where ongoing research, support, and heightened disease awareness for people with extremely high triglycerides come together to change lives — 'We'll Get There Soon'
We'll Get There Soon (Graphic: Business Wire)
The campaign features a dedicated website, www.LowerTriglycerides.com, along with social media pages on Instagram and Facebook offering a platform for people affected by FCS to share their experiences. A key focus is educating the community about expert guidelines, which recommend maintaining triglyceride levels below 500 mg/dL to reduce the risk of acute pancreatitis1-3.
Arrowhead hosted a launch event at its
“My journey to diagnosis was a difficult one that ended after a decade-long diagnostic process and countless hours of research, learning about FCS, and finally presenting the idea to my doctor,” Julie explained. “Despite my eventful history with this condition, including countless hospitalizations, multiple surgeries, a radical hysterectomy, relocating and moving my family to be closer to my trusted doctors, I remain optimistic about the future for FCS patients.” Excited by what the future holds, Julie is also working with the Arrowhead team contributing patient insights to support and inform efforts for people with FCS because she believes, “Hope is on the horizon.”
“We are humbled to play a small role in amplifying the voices of those affected by FCS and bringing them hope. Julie’s presence in our offices reminds us of why we do what we do every day and reaffirms one of Arrowhead’s core values: patients — making people’s lives better,” said Alexendra Roeser, Director of Patient Advocacy at Arrowhead.
Today, on FCS Awareness Day, and beyond, Arrowhead is on a mission to create awareness #ForFCS. Learn more at www.LowerTriglycerides.com.
About Familial Chylomicronemia Syndrome
Familial chylomicronemia syndrome (FCS) is a severe and rare genetic disease often caused by various monogenic mutations. FCS leads to extremely high triglyceride (TG) levels, typically over 880 mg/dL. Such severe elevations can lead to various serious signs and symptoms including acute and potentially fatal pancreatitis, chronic abdominal pain, diabetes, hepatic steatosis, and cognitive issues. Currently, there are no therapeutic options that can adequately treat FCS.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
________________
- AACE/ACE Guidelines: Handelsman Y et al. Endocr Pract. 2020;26(10):1196-1224.
- ACC/AHA Guidelines: Grundy SM et al. Circulation. 2019;139(25):e1082-e1143.
- NLA Guidelines: Jacobson TA et al. J Clin Lipidol. 2015;9(2):129-169.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241101712119/en/
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
Media:
LifeSci Communications, LLC
Kendy Guarinoni, Ph.D.
724-910-9389
kguarinoni@lifescicomms.com
Source: Arrowhead Pharmaceuticals, Inc.
FAQ
What is the purpose of Arrowhead Pharmaceuticals' 'We'll Get There Soon' campaign?
What dietary restrictions do FCS patients face according to ARWR's campaign?
What platforms is Arrowhead Pharmaceuticals using for their FCS awareness campaign?